October 1, 1995

Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer.

Key Points

Key points are not available for this paper at this time.

Abstract

This randomized trial demonstrates a survival benefit in anthracycline-refractory ABC. NVB was well tolerated and demonstrated activity superior to ALK in anthracycline-refractory ABC, without compromising QL. Based on activity of single-agent NVB in this difficult-to-treat patient population, investigations of NVB in combination with other anticancer drugs are warranted.

اسأل الذكاء الاصطناعي

Bookmark

Cite This Study

Jones et al. (Sun,) studied this question.

synapsesocial.com/papers/69ddc9eaa051b8e25be9395c https://doi.org/https://doi.org/10.1200/jco.1995.13.10.2567

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Phase-II study of Navelbine in advanced breast cancer.1989 · 132 citations
2Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy.1993 · 328 citations
3Navelbine (NVB) as a salvage treatment for advanced breast cancer pefractory to anthracyclines1993 · 1 citations
4Vinorelbine as first-line chemotherapy for metastatic breast carcinoma.1994 · 190 citations
5The importance of dose intensity in chemotherapy of metastatic breast cancer.1984 · 892 citations

اسأل الذكاء الاصطناعي

Bookmark